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Abstract
Background: Adult-onset Still’s disease (AOSD), a rare autoinflammatory disorder, resembles systemic juvenile
idiopathic arthritis (SJIA). The superimposable systemic clinical features of AOSD and SJIA suggest both clinical
phenotypes represent the same disease continuum with different ages of onset. To further characterize the similarity
between AOSD and SJIA at the molecular level, 2 previously identified response gene sets in SJIA were used to
investigate how genes that respond to interleukin (IL)-1β inhibition with canakinumab in SJIA patients behave in
AOSD patients with active disease prior to IL-1β targeting therapy, relative to healthy subjects.
Findings: All genes downregulated in SJIA patients following canakinumab treatment were upregulated in most
patients with active AOSD prior to canakinumab treatment, relative to healthy subjects. A few patients with milder AOSD
had expectedly gene-expression patterns that resembled those in healthy subjects. Comparison of the gene-expression
patterns with neutrophil counts showed a correlation between elevated neutrophil numbers and upregulation of
canakinumab-responsive genes. Correspondingly, most genes upregulated following canakinumab treatment in
patients with SJIA patients were downregulated in the majority of AOSD patients.
Conclusions: These results further support the concept of a Still’s disease continuum that includes both a pediatric/
juvenile onset (SJIA) and adult onset (AOSD) form.
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Findings
Background and research hypothesis
Adult-onset Still’s disease (AOSD) is a rare autoinflamma-
tory disorder resembling the pediatric syndrome systemic
juvenile idiopathic arthritis (SJIA) [1, 2]. Patients with ei-
ther AOSD or SJIA exhibit classical clinical and laboratory
features, including daily spiking fever, arthralgia or arth-
ritis, evanescent rash, and increased white blood cell count
(mainly neutrophils) [1, 3–5]. Because of the superimpos-
able systemic clinical features of SJIA and AOSD, it has
been suggested that these clinical phenotypes represent
the same disease continuum with different ages of onset.
It has, therefore, been proposed that patients with the sys-
temic features of SJIA but without arthritis be classified as
having Still’s disease based on analogy with AOSD [2]. Of
note, when children were first described in the 19th cen-
tury with what is now called “SJIA,” the term “Still’s dis-
ease” was used [6].
In addition to having a similar clinical picture, evidence
suggests that AOSD and SJIA are also comparable on a
molecular level. Both conditions are characterized by acti-
vation of the innate immune system, including elevations
of inflammatory cytokines and proteins such as interleukin
(IL)-1, IL-6, IL-18, and S100 proteins [7–11]. Moreover,
patients with AOSD or SJIA can experience macrophage
activation syndrome, a severe, potentially life-threatening
complication [12, 13].
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The most compelling evidence demonstrating that AOSD
and SJIA largely share the same pathophysiology may be
that both are highly responsive to IL-1 inhibition. Transla-
tional and clinical studies suggest that the proinflammatory
cytokine IL-1 plays a pivotal role in the pathogenesis of
SJIA. Serum samples from patients with SJIA have been
shown to induce the transcription of innate immunity
genes, including IL-1, in healthy peripheral blood mono-
nuclear cells [14]. In addition, these cells in patients with
SJIA demonstrated a possible IL-1–driven signature [15].
More importantly, the pivotal role of IL-1 in the pathogen-
esis of SJIA has been validated by the clinical efficacy of
canakinumab — a high-affinity human monoclonal anti −
IL-1β antibody — in phase 2 and 3 SJIA trials [16, 17]. Evi-
dence for the clinical efficacy of IL-1 inhibition in adult
patients with moderate to severe AOSD, including those re-
sistant to standard therapy, is principally derived from small
observational studies [10, 18–22]. Further, results from 1
open-label, randomized trial suggest that IL-1 inhibitor
therapy is effective in AOSD and may minimize or avoid
the need for glucocorticoids in most patients [23, 24].
Analyses of gene-expression profiles can be clinically
useful not only for disease classification, diagnosis, and
prognosis but also to identify disease-specific treatment
effects that target underlying pathologic mechanisms. In
a previous gene-expression analysis using blood samples
from patients with SJIA treated with canakinumab in phase
3 trials, canakinumab strongly repressed many inflamma-
tion- and innate-immunity–related genes, including those
in the IL-1–signaling pathways, in canakinumab re-
sponders [25]. To evaluate if AOSD is also an IL-1 − driven
condition, the present study investigated how genes that
respond to IL-1β inhibition with canakinumab in patients
with SJIA behave in patients with active AOSD, relative to
healthy subjects. It was hypothesized that because AOSD
and SJIA are closely related conditions, genes that respond
to canakinumab treatment in patients with SJIA may be
inversely dysregulated in patients with AOSD prior to
anti − IL-1β therapy. If this proved to be the case, then
a similar set of genes in AOSD should be responsive to
anti − IL1-β therapy.
Patients and methods
In the previous SJIA gene-expression analysis, pre- and
post-canakinumab treatment blood samples were ob-
tained from patients participating in two phase 3 clin-
ical trials (β-SPECIFIC-1 and β-SPECIFIC-2) [25]. To
identify canakinumab-responsive genes, baseline (pretreat-
ment) and day-3 (post-treatment) samples were compared
from patients who clearly benefited from canakinumab
treatment by achieving a ≥50 % improvement by adapted
pediatric American College of Rheumatology criteria at
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Fig. 1 Comparison of gene-expression data for patients with AOSD prior to canakinumab treatment and healthy subjects. Dots show expression levels of
individual genes where the average value in healthy subjects is shown on x axis and the average value in patients with AOSD is shown on y axis. Genes
represented in red are those previously found to respond to canakinumab treatment in patients with SJIA. Genes downregulated by canakinumab in
patients with SJIA were upregulated in untreated patients with AOSD, relative to healthy subjects (plot on left). Correspondingly, most genes previously
found to be upregulated by canakinumab in SJIA were downregulated in untreated patients with AOSD (plot on right). P values refer to significance of
differential expression of canakinumab gene sets
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day 15 (median age, 9 years). The canakinumab-response
signature in SJIA included genes that were significantly
differentially expressed (paired t-test: P <.05; ≥1.5-fold
differential expression) at day 3 compared with base-
line, represented by 577 downregulated probe sets and
728 upregulated probe sets.
For the present gene-expression analysis in AOSD,
blood samples were obtained from 17 patients (median
age, 37 years; 59 %, female) under investigation for the
efficacy of canakinumab in patients with active AOSD
[NCT02204293] [26]. Blood samples were also obtained
from 19 healthy subjects included in the control group
(median age, 26 years; 79 %, female). The probe sets iden-
tified in the blood samples of patients with SJIA were used
for supervised visualization of gene-expression values in
the untreated patients with AOSD and healthy subjects.
The data were median-centered per gene to visualize the
direction of differential expression more clearly.
Fig. 2 Color-coded expression values of genes down regulated following canakinumab treatment in patients with SJIA. Gene-expression values are
shown for healthy subjects and patients with AOSD prior to canakinumab treatment. Transcripts shown in rows and patient samples in columns. For
patients with AOSD, baseline (BL) blood cell counts are also provided (bottom)
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Whole blood samples were collected in PAXgene Blood
RNA tubes (Qiagen, Hilden, Germany) and stored at −80 °
C. Total RNA was subsequently isolated with the PAXgene
Blood RNA Kit (Qiagen). The synthesis of cDNA was per-
formed using the Ovation® RNA Amplification System V2
including the Ribo-SPIA® amplification process according
to the instructions of the manufacturer (NuGEN Technolo-
gies Inc., San Carlos, CA). The amplification process was
performed in 3 stages: (1) a 1st-strand cDNA synthesis with
oligo(dT) primers and Ovation WB Reagent (NuGEN), (2)
a 2nd-strand cDNA synthesis, and (3) a single-primer, lin-
ear isothermal amplification (SPIA™, NuGEN) that pro-
duced amplified single-stranded biotin-labeled cDNA. The
cDNA was hybridized to GeneChip® Human Genome
U133 Plus 2.0 Array as specified by the manufacturer
(Affymetrix, Inc., Santa Clara, CA). Gene-expression
values were stored in CEL files that were used for ro-
bust multi-array average normalization with the affy and
Fig. 3 Color-coded expression values of genes up regulated following canakinumab treatment in patients with SJIA. Gene-expression values are
shown for healthy subjects and patients with AOSD prior to canakinumab treatment. Transcripts shown in rows and patient samples in columns.
For patients with AOSD, baseline (BL) blood cell counts are also provided (bottom)
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gcrma R packages. Normalized data were then scaled to a
trimmed mean value of 150. The significance of gene-set
enrichment was estimated using the ROAST method
as implemented in R, [27] applying 10,000 rotations to
the data set.
Results and discussion
The behavior of canakinumab responsive genes in patients
with AOSD and healthy subjects is shown in Figs. 1, 2,
and 3. Figure 1 displays the average expression values in
the AOSD and healthy groups, whereas Figs. 2 and 3 show
the relative expression values in all individuals separately.
All genes that were downregulated following canakinumab
treatment in patients with SJIA showed upregulation in
most patients with AOSD, relative to healthy subjects
(Figs. 1 and 2). These upregulated genes included various
genes related to innate immunity, including several mem-
bers of the IL-1–signaling pathways, e.g. IL-1β, IL-1RAP,
IL-1RN, IL-1R1, and IL-1R2. A few patients with milder
AOSD had gene-expression profiles that rather resembled
those of the healthy subjects (Fig. 2). Comparison of the
AOSD gene-expression patterns with neutrophil counts
showed that upregulation of IL-1 − associated gene ex-
pression was particularly pronounced in patients with
strongly elevated neutrophil numbers and that patients
with comparatively low neutrophil counts showed expres-
sion of canakinumab responsive genes at levels similar to
healthy subjects. Correspondingly, most of the genes that
were found to be upregulated following canakinumab
treatment in patients with SJIA showed downregulation in
most AOSD patients (Figs. 1 and 3), with the transcrip-
tional patterns slightly more heterogeneous. These genes
included many regulators of proliferation and immune-
cell activity, such as AKT3, CD24, CD28, CD3D, CD6,
CD69, CDC25B, and CDC7.
While relatively new, gene expression allows analysis of
hundreds and thousands of different genes at a given time
instead of a handful of candidates, and represents the
most advanced and comprehensive approach to screening
gene activity as well as molecular networks involved in the
innate immune system. Nonetheless, SJIA and AOSD are
rare autoinflammatory conditions; therefore, large pro-
spective and longitudinal trials are difficult to generate
which explains the relatively small sample size of this ana-
lysis. Disease duration and severity, prior treatment with
other biologics and concomitant corticosteroid exposure
during the trial may have influenced the SJIA findings.
With regard to the AOSD baseline analysis it should be
noted that future analysis needs to confirm the hypothe-
sized treatment response and downregulation of canaki-
numab responsive genes.
In conclusion, the results of this gene-expression analysis
are consistent with and further support the concept of a
Still’s disease continuum that includes both a pediatric/
juvenile onset (SJIA) and adult onset (AOSD). These find-
ings support further clinical evaluation of anti− IL-1β ther-
apy in patients with AOSD given that AOSD appears to be
an IL-1–driven condition similar to SJIA.
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